<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215149</url>
  </required_header>
  <id_info>
    <org_study_id>IAVI B003/ IPCAVD-004</org_study_id>
    <nct_id>NCT01215149</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults</brief_title>
  <official_title>A Phase 1 Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Safety and Immunogenicity of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HIV Vaccine Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ragon Institute of MGH, MIT and Harvard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of Ad26.ENVA.01 and
      Ad35-ENV in low-risk for HIV-uninfected healthy adults administered in heterologous and
      homologous prime-boost regimens at different time intervals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double-blind placebo-controlled trial assessing the order of
      vector priming and boosting (Ad26 versus Ad35), the timing of boost (3 versus 6 months) and
      the homologous versus heterologous regimen at the 3-month time interval. Groups A-D will be
      enrolled in Boston, MA, USA, Groups E-H will be enrolled at the East African Clinical
      Research Centres and Groups I-L will be enrolled at the South African Clinical Research
      Centres.

      Volunteers will be screened up to 56 days before vaccination and will be followed for 12
      months after the second vaccination.

      Approximately 212 volunteers will be randomized to receive either vaccine or placebo within a
      group (A-L); Groups A-D, Groups E-H and Groups I-L will be randomized separately. Up to 7%
      over-enrolment (approximately 15 volunteers) will be allowed to facilitate enrolment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>15-18 months approximately</time_frame>
    <description>To evaluate the safety and tolerability of Ad26.ENVA.01 and Ad35-ENV administered in heterologous and homologous prime-boost regimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the immunogenicity of Ad26.ENVA.01 and Ad35-ENV administered in heterologous prime-boost regimens at 3 versus 6 month intervals
To evaluate the immunogenicity of Ad26.ENVA.01 and Ad35-ENV administered in heterologous and homologous prime-boost regimens at 3 month interval
To evaluate anti-vector immunity induced by Ad26.ENVA.01 and Ad35-ENV administered in heterologous and homologous prime-boost regimens</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 6. Vaccine:Placebo=10:3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-ENVA at Month 0 followed by Ad26.ENVA.01 at Month 6. Vaccine:Placebo=10:3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=10:3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=10:3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad35-ENV vaccine</intervention_name>
    <description>Recombinant adenovirus serotype 35 vector vaccine 5x10^10 vp, delivered IM</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_label>Group L</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.ENVA.01 vaccine</intervention_name>
    <description>Recombinant adenovirus serotype 26 vector vaccine, 5x10^10 vp delivered IM</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_label>Group K</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo Control</intervention_name>
    <description>Colorless 10mm Tris/HCl buffer</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_label>Group K</arm_group_label>
    <arm_group_label>Group L</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female, as assessed by a medical history, physical exam, and
             laboratory tests;

          -  At least 18 years of age on the day of screening and has not reached his/her 51st
             birthday on the day of first vaccination;

          -  Willing to comply with the requirements of the protocol and available for follow-up
             for the planned duration of the study;

          -  In the opinion of the Principal Investigator or designee, and based on Assessment of
             Informed Consent Understanding (AOU) results, has understood the information provided
             and potential risks linked to vaccination and participation in the trial; written
             informed consent will be provided by the volunteer before any study-related procedures
             are performed;

          -  Willing to undergo HIV testing, risk reduction counselling, receive HIV test results
             and committed to maintaining low risk behaviour for the trial duration as defined by
             the protocol;

          -  If a female of childbearing potential, willing to use an effective non-barrier method
             of contraception (oral or injectable hormonal contraceptive; intrauterine device
             [IUD]) from screening until at least 4 months after the last study vaccination;

          -  Assessed by the clinic staff as being at &quot;low risk&quot; for HIV infection on the basis of
             sexual behaviours within the 12 months prior to enrolment;

          -  All female volunteers must be willing to undergo pregnancy tests at time points
             indicated in the protocol and must test negative prior to each study vaccination;

          -  All sexually active males (unless anatomically sterile) must be willing to use an
             effective method of contraception (such as consistent condom use) from the day of
             first vaccination until at least 4 months after the last vaccination;

          -  Willing to forgo donations of blood or any other tissues during the study and, for
             those who test HIV positive due to trial vaccination (vaccine-induced HIV
             seropositivity), until the anti-HIV antibody titers become undetectable.

        Exclusion Criteria

          -  Confirmed HIV-1 or HIV-2 infection;

          -  Any clinically relevant abnormality on history or examination including history of
             immunodeficiency or autoimmune disease; use of systemic corticosteroids (the use of
             topical or inhaled steroids is permitted); immunosuppressive, anticancer,
             antituberculosis or other medications considered significant by the investigator
             within the previous 6 months;

          -  Any clinically significant acute or chronic medical condition that is considered
             progressive, or in the opinion of the investigator, makes the volunteer unsuitable for
             participation in the study;

          -  Reported risky behaviour for HIV infection within 12 months prior to vaccination, as
             defined by the protocol

          -  If female, pregnant or planning a pregnancy within 4 months after last vaccination; or
             lactating;

          -  Asthma requiring high-dose oral or inhaled corticosteroids;

          -  Fever &gt; 100.4° F/38.0° C within 72 hours prior to vaccine administration;

          -  Bleeding disorder that was diagnosed by a physician (e.g., factor deficiency,
             coagulopathy or platelet disorder that requires special precautions) (Note: A
             volunteer who states that he or she has easy bruising or bleeding, but does not have a
             formal diagnosis and has IM injections and blood draws without any adverse experience
             is eligible);

          -  History of splenectomy;

          -  Any abnormal laboratory parameters as defined by the protocol;

          -  Receipt of live-attenuated vaccine within the previous 60 days or planned receipt
             within 60 days after vaccination with Investigational Product (within 14 days for live
             attenuated influenza vaccine [LAIV]); or receipt of other vaccine (e.g., influenza,
             pneumococcal), allergy treatment with antigen injections or tuberculin skin test
             within the previous 14 days or planned receipt within 14 days after vaccination with
             Investigational Product;

          -  Receipt of blood transfusion or blood-derived products within the previous 3 months;

          -  Participation in another clinical trial of an Investigational Product currently,
             within the previous 3 months or expected participation during this study;

          -  Receipt of another investigational HIV vaccine candidate (Note: receipt of an HIV
             vaccine control or placebo will not exclude a volunteer from participation if
             documentation is available and the Medical Monitor gives approval);

          -  History of severe local or systemic reactogenicity to vaccines (e.g., anaphylaxis,
             respiratory difficulty, angioedema);

          -  Confirmed diagnosis of active hepatitis B, hepatitis C or active syphilis;

          -  Seizure disorder: A participant who has had a seizure in the last 3 years is excluded.
             (Not excluded: a participant with a history of seizures who has neither required
             medications nor had a seizure for 3 years.);

          -  Psychiatric condition that precludes compliance with the protocol. Specifically
             excluded are persons with psychoses within the past 3 years, ongoing risk for suicide,
             or history of suicide attempt or gesture within the past 3 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey Baden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital, Boston, MA, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gaudensia Mutua, MB ChB, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenya AIDS Vaccine Initiative, Kangemi, Kenya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Etienne Karita, MD, M.Sc., MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Projet San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda-Gail Bekker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Desmond Tutu HIV Foundation-Emavundleni Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Glenda Gray, MBBCH, FCPaeds(SA)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Perinatal HIV Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liesl Page-Shipp</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aurum Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenya AIDS Vaccine Initiative</name>
      <address>
        <city>Kangemi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Projet San Francisco</name>
      <address>
        <city>Kigali</city>
        <country>Rwanda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation-Emavundleni Research Centre</name>
      <address>
        <city>Cape Town (Nyanga)</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurum Institute</name>
      <address>
        <city>Klerksdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit</name>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Rwanda</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.iavi.org</url>
    <description>International AIDS Vaccine Initiative</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2010</study_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

